Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection - Wikidata - wikimedia - TriplyDB

Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection

Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection

http://www.wikidata.org/entity/Q24672964

about

Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice In vitro selection of clinically relevant bevirimat resistance mutations revealed by "deep" sequencing of serially passaged, quasispecies-containing recombinant HIV-1 A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat HIV type 1 Gag as a target for antiviral therapy Virus maturation as a new HIV-1 therapeutic target Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication.Structural and functional insights into the HIV-1 maturation inhibitor binding pocket Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors Ionic liquid solutions as extractive solvents for value-added compounds from biomass Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396 The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates Novel approaches to inhibiting HIV-1 replication.Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid.Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.Inhibitory effect of aqueous Dandelion extract on HIV-1 replication and reverse transcriptase activity Metabolic and functional diversity of saponins, biosynthetic intermediates and semi-synthetic derivatives Conjugates of betulin derivatives with AZT as potent anti-HIV agents.HIV entry inhibitors and their potential in HIV therapy Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.New betulinic acid derivatives as potent proteasome inhibitors HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors.Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice.HIV-1 antiretroviral drug therapy.Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.Anti-AIDS agents 88. Anti-HIV conjugates of betulin and betulinic acid with AZT prepared via click chemistry Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors.HIV-1 Capsid Inhibitors as Antiretroviral Agents Critical role of conserved hydrophobic residues within the major homology region in mature retroviral capsid assembly.New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1.Recent progress in antiretrovirals--lessons from resistance Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity.Isolation and characterization of a small antiretroviral molecule affecting HIV-1 capsid morphology.Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457)Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.Insights into the activity of maturation inhibitor PF-46396 on HIV-1 clade C Pediatric antiretroviral therapy.

P2860

Q21092230-59C819D7-996B-4375-AEE0-327AC39A5AB6 Q24599377-46F055E4-4050-4334-B7F5-BE90AA7FF911 Q24606079-97E872B6-8493-4AC5-BE4F-9D3BF6DF5155 Q24614498-500D28EF-C9AA-42D5-A4F0-BC8B5AE5B105 Q24642446-58FA2B5C-848E-4823-8974-9DCD1CFBAC07 Q27324193-2B0A6B16-4257-464B-8DD4-5018A4D59BE4 Q28485054-9AC2F5A6-A138-4C0A-B9B0-C86B40D6A08A Q28554482-0E86826E-67EF-4677-AD49-1095C4019270 Q28649851-B17EEF6F-DBD2-4D54-9BC9-B319E5CCD26C Q28828191-192CC909-72AB-40CB-94E5-E2D74B53408C Q33557807-9C599603-77D8-4491-A9D8-78E3A907A952 Q33624690-008C527F-11AF-450C-A1DE-4ABB6335DF47 Q33774977-134595DE-4951-4A3A-8672-F213A14A3CAD Q33814879-D16DD57C-EBAC-45A5-89CE-8CD8491B4E71 Q33864444-CBA7B00B-562E-4673-861C-172C94747B5B Q34037355-A3057DE1-CEFA-4EA8-A4EF-E82EC969507B Q34073041-FFFCB267-F055-41C7-A7FB-C0F168078200 Q34441998-72BB5060-E81C-43E0-B21D-AAC16E37CBD2 Q34468057-7ED4A7D6-EF4B-4450-8EDC-53FE98FD7D08 Q34595921-E93792BB-3B90-47F0-8C6C-B167041F37D2 Q34885660-10440ACE-E93B-49CF-A359-ADDD5CBF2BAE Q35209514-39374E7C-335A-48D3-BDC6-CBBB3EBFB563 Q35761626-9133D971-2CB3-4091-AF6E-3DCB41B3ECFA Q35832693-B76299E5-9B48-45DC-BA6E-EA72047BEEFC Q35853012-FAF953E0-2503-4B6C-B9FB-6491A5CAF6DE Q35992805-1F4C2351-F52A-44B0-BD2D-B8AD6D668C5D Q36034205-CD65E184-85CC-4663-97A9-3669E4DB9243 Q36185528-0652A768-08FD-463C-8560-943405E88CA1 Q36340098-A1DEB780-01E8-463F-9565-09C27F620BAD Q36672006-109148B6-0892-4888-B68D-207AE491A7F1 Q36673166-4FD34871-2631-4A2B-8899-0DD500CA58FC Q36691642-CC5C31BC-92DC-4640-8935-11A855367A08 Q36967857-CF079DBD-2C8B-4E78-B2C5-7DCF07A6B2CC Q36996295-CEFE2AEC-8272-4988-9D5C-9BE53CF51A11 Q37162931-E4B7BDDF-60CB-43E9-B232-6D5384787FBB Q37192174-4B722045-B371-4765-8478-532468A2C840 Q37330178-5023DB1A-0BA8-4625-92F0-FC6B2F5F6D67 Q37450688-0E0ED02C-07CA-49FB-8C89-0995DDB5AFB6 Q37676344-9D5EC2D0-5452-4E26-A6AD-4FDDAE8757B8 Q37816389-3102DDBE-1729-4C59-94CA-0B90DFBC26C6

P2860

Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection

http://www.wikidata.org/entity/Q24672964

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Phase I and II study of the sa ...... munodeficiency virus infection

@ast

Phase I and II study of the sa ...... munodeficiency virus infection

@en

Phase I and II study of the sa ...... munodeficiency virus infection

@nl

type

label

Phase I and II study of the sa ...... munodeficiency virus infection

@ast

Phase I and II study of the sa ...... munodeficiency virus infection

@en

Phase I and II study of the sa ...... munodeficiency virus infection

@nl

prefLabel

Phase I and II study of the sa ...... munodeficiency virus infection

@ast

Phase I and II study of the sa ...... munodeficiency virus infection

@en

Phase I and II study of the sa ...... munodeficiency virus infection

@nl

P1433

Q24672964-AB134271-3806-4F4C-B6DA-5A8CD1240AF9

P1476

Q24672964-894E8096-1CBE-451D-9236-1D3DC89B2801

P2093

Q24672964-215AA72B-37CB-48B9-97D9-460E37BDAA2D

Q24672964-4702160F-51D1-4FD7-A205-4F0EF222648D

Q24672964-76F04BFF-0ABA-4903-9DD4-A4C4085BBF94

Q24672964-88C936C3-19FF-4970-8711-B11BDE485170

Q24672964-8D2081B1-8E0D-4F0B-8217-51E054F1D31A

Q24672964-90CB351D-12FE-4A53-BEF1-31EFD83C865B

Q24672964-B7B68E80-2E61-4D44-B88D-4A0D7BB70914

Q24672964-F6061A22-5151-4338-B292-A0732993DBDB

P2860

Q24672964-06003A25-D3A3-4D43-A451-C06060AE75D9

Q24672964-0733D733-886C-443A-BE03-C673154E9692

Q24672964-0B9ACD3C-0996-45E6-B44E-5B6CEEB3B009

Q24672964-4CD94044-A5D9-4621-841A-9A622AD1966D

Q24672964-5D7B1A19-7F5C-4DC5-B46E-614850DC381F

Q24672964-5FC942D4-A09C-434B-A4DC-8D56179FCFB2

Q24672964-8B9B65F6-7D67-4797-A77C-49D377C50B34

Q24672964-A696EE9A-80E6-4056-A6C5-6F05663D748F

Q24672964-B03D998C-4B9F-48CB-A1B6-1840F338B879

Q24672964-DA28F304-3787-46DE-AD5A-FF72690D22B4

P304

Q24672964-6719C4CD-2005-4C76-9B9B-312ADE8D60FF

P31

Q24672964-0F302159-5E6C-44FB-9EEE-866C2B5AD882

P3181

Q24672964-3C538B85-11CC-4270-99DD-015362ED1A7E

P356

Q24672964-EE85EC73-DB8E-4251-9B67-19AD039F8B38

P407

Q24672964-D3E23399-B007-4B00-B2E8-CAA9B2AFF039

P433

Q24672964-2B162249-8160-42B5-89A1-04DB26BABB59

P478

Q24672964-4B665D5E-614E-410B-9F58-3973F769900E

P577

Q24672964-2D4C428C-95ED-482C-B24E-232258B5A848

P698

Q24672964-E864C508-4483-4AB5-9236-2935DB3DD770

P921

Q24672964-060148EF-EB7C-47B1-A449-4F3E412CDA36

Q24672964-24A4CA0F-291F-4602-8A0C-78252D9B2A2E

Q24672964-38FCBDA8-917E-4EC7-8604-9638D933CF37

P932

Q24672964-EE517507-2774-41D8-8252-019947B49287

P3181

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Phase I and II study of the sa ...... munodeficiency virus infection

@en

P2093

Abayomi Ogundele

http://www.w3.org/2001/XMLSchema#string

Alan Forrest

http://www.w3.org/2001/XMLSchema#string

David E Martin

http://www.w3.org/2001/XMLSchema#string

Graham P Allaway

http://www.w3.org/2001/XMLSchema#string

John Wilton

http://www.w3.org/2001/XMLSchema#string

Judy Doto

http://www.w3.org/2001/XMLSchema#string

Karl Salzwedel

http://www.w3.org/2001/XMLSchema#string

Patrick F Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers

Decay characteristics of HIV-1-infected compartments during combination therapy

Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.

Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.

Nevirapine resistance after single dose prophylaxis.

Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation.

PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.

Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.

Dynamics of HIV-1 and CD4+ lymphocytes in vivo.

Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals.

P304

3574-81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2251633

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/AAC.00152-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17638699

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

pharmacodynamics

P932

2043264

http://www.w3.org/2001/XMLSchema#string